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Background: Counseling and anticipatory guidance of the expected course of treatment
for women newly diagnosed with metastatic breast cancer (MBC) are difficult due to mul-
tiple factors influencing survival following MBC therapy. In order to better tailor counseling
at the onset and through the duration of MBC we used non-clinical trial data to better
characterize real life experience of sequential MBC treatment. We examined the following
aims: (1) What demographic and tumor characteristics are predictive of survival in MBC?
(2) What is the median duration of each sequential chemotherapy regimen and subsequent
survival of women following each sequence of chemotherapy regimen in MBC?
Methods: Retrospective study included 792 women diagnosed from January 1999 through
December 2009 at the University of Pittsburgh Cancer Institute Breast Cancer Program.
Results: Median duration of sequential chemotherapy regimen and median survival from
completion of sequence of chemotherapy regimens were relatively short with a wide
range of treatment duration and survival. Characteristics for poor survival included hor-
mone status, human epidermal growth factor receptor-2 (HER 2/neu) status, and increased
number and type of metastatic sites. Women who took more than the second sequential
chemotherapy regimens had no more than median 3 months of treatment duration and
6 months survival from treatment termination.
Discussion: Median clinical response and survival shorten with sequential chemotherapy
regimen but with wide ranges. The rare clinical response of the minority should not set
the standard for treatment expectations. All cancer clinicians, including oncology nurses,
must ensure that patients are receiving tailored counseling regarding their specific risks
and benefits for sequential MBC chemotherapy.
Keywords: metastatic breast cancer, chemotherapy, sequential treatment, survival, treatment counseling
INTRODUCTION
It is estimated that 160,000 United States women are living with
metastatic breast cancer (MBC) with median survival of 2–3 years
(1). National data base analysis (2, 3) as well as local experience (4)
indicates that chemotherapy treatment until the last months before
death from MBC is common practice due to multiple etiologies.
First, the heterogenic nature of breast cancer and the variability of
treatment response allows for several chemotherapies to be utilized
for MBC treatment in sequential fashion without clear stopping
rules. Next, there are believed to be some modest survival advan-
tages (5) and quality of life benefits in women receiving more,
rather than less chemotherapy in MBC. Additionally, it is well
documented that in advanced cancer, patients prefer chemother-
apy with minimal potential benefit, rather than termination of
anti-tumor treatment (6, 7).
Lastly the national consensus guidelines for cancer practice
encourage the use of sequential chemotherapy to treat MBC (8).
The 2013 National Comprehensive Cancer Network recommenda-
tion for systemic metastatic chemotherapy is as follows (8): “Fail-
ure to achieve a tumor response to three sequential chemotherapy
regimens or an Eastern Cooperative Oncology Group performance
status of three or greater was believed to be an indication for
supportive therapy only. In this context, failure to respond to
a chemotherapy regimen means the absence of even a marginal
response to the use of a given chemotherapy regimen. Response to
a chemotherapy regimen followed by progression of disease is not
considered a failure to experience response.” Essentially this rec-
ommendation speaks to wide heterogeneity in treatment response
in MBC, even among women who have been heavily treated with
chemotherapy.
This wide range of treatment response leads to initial counsel-
ing for patients with MBC and it can portray MBC as a “chronic”
disease similar to hypertension and diabetes, probably not cur-
able but very treatable. This explanation may be true for specific
subsets of women with MBC [low volume disease, estrogen recep-
tor (ER) – positive, human epidermal growth factor receptor-2
(HER 2/neu) – positive], but leaves many women poorly prepared
for the progressive and ultimately life ending experience of MBC.
The available clinical evaluation of chemotherapy in MBC is usu-
ally direct comparison of one chemotherapy regimen vs. another
to determine survival and clinical benefit endpoints (9–16).In a
non-clinical trial environment, the patient clinical experience, and
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survival benefit of sequential palliative chemotherapy for MBC
have not been well described. This leaves little information for the
cancer clinician on which to base their treatment counseling for
MBC patients. In order to provide a data base for evidence based
approach to MBC we conducted a retrospective study with a large
clinical data collected for 10 years. Women diagnosed with MBC
from this academic based practice were examined to answer the
following research questions:
1. What are the influences of demographic and tumor character-
istics on survival with MBC?
2. What are the median and ranges of durations of sequential
chemotherapy regimens in MBC and what are the median and
ranges of survival after the termination of each of last sequential
chemotherapy regimen?
MATERIALS AND METHODS
This study was based on an Institutional Review Board (IRB)
approved protocol for reviewing medical record about women
diagnosed with MBC at one large urban practice of the University
of Pittsburgh Cancer Institute Breast Cancer Program. Women
gave informed consent to having their medical chart reviewed
for breast cancer studies with a global consent for cancer registry
at the onset of their breast cancer care. The clinic center offers
comprehensive counseling and cancer treatment services includ-
ing administration of chemotherapy, supportive cancer therapies,
and psychological counseling. Inclusion criteria included women
at 18 or older years of age with MBC diagnosed between January
1999 and December 2009. Second opinion visits were not included.
Patients with MBC were identified from daily clinic lists with
disease stage. Medical record review confirmed the diagnosis of
MBC through clinical, radiological, or pathologic confirmation.
There were 38 demographic and historical items captured with
entry into the database with 14 entries abstracted monthly accord-
ing to a chart abstraction and quality assurance protocol. Among
those demographic, pathologic, and clinical variables, for the pur-
pose of this study, following variables were selected to use in
analysis: age, race, number of metastatic sites, metastatic loca-
tion, ER and/or progesterone receptor (ER/PR) status, and HER 2
status. Systemic chemotherapy was evaluated for their sequences.
The primary tool for abstraction was the clinic note, usually com-
pleted monthly with patient visit. Abstraction was completed by
registered nurses with clinical experience in breast cancer.
Bivariate analyses were performed to describe descriptive pat-
terns and relationships among key variables. These analyses
included Wilcoxon rank sum test to examine bivariate relation-
ships between variables. Log-rank test and Kaplan–Meier’s graph
were conducted to evaluate the relationship between categorical
variables and survival. Data were collected and entered into an
EXCEL data base and exported to SAS 9.2 for analysis. Two-tailed
P-value <0.05 was considered significant.
OPERATIONAL DEFINITIONS
• Tumor characteristics: ER/PR and HER 2 status were determined
from metastatic sites when available. If metastatic tissue was
not present then primary breast tissue reports were used for
determining ER/PR and HER 2 status.
• Clinical benefit: it is difficult to measure treatment efficacy dur-
ing sequential palliative chemotherapy. The standard Response
Evaluation Criteria In Solid Tumors (RECIST) criteria or indica-
tors of tumor progression, radiographic progression, or increase
in tumor marker,become less relevant if the patient remains clin-
ically stable, or conversely, experiences an increase in symptom
ontology without significant tumor progression. The term “clin-
ical benefit” matches the approved language from the National
Cancer Institute in determining clinical endpoints for advanced
cancer (14). Clinical benefit is measured as the time until need
for change in chemotherapy or hormonal therapy due to dis-
ease progression or intolerance to therapy rather than formal
measures of radiographic progression. These determinations
were made by a trained registered nurse reading the sequential
monthly clinic notes written by the physician, nurse practitioner
or physician assistant and making a protocolized determination
regarding the reason for treatment change. Clinical benefit was
utilized as a surrogate for time of disease progression.
• Sequential chemotherapy category: patient visits were abstracted
monthly at the first visit of the month. Systemic treatments
including chemo and hormone therapy were coded and then
counted according to months of treatment. A chemotherapy
regimen (i.e., a set of chemo drugs) was counted as first, sec-
ond, etc., regardless of other systemic treatments. For example,
if one chemotherapy regimen was initiated as a second treat-
ment, following several months of hormonal therapy, this was
counted as first chemotherapy and subsequent duration of ther-
apy and survival following completion of therapy was calculated
accordingly.
RESULTS
BREAST CANCER CHARACTERISTICS
The database consists of 792 women diagnosed with MBC from
January 1999 through December 2009. In this cohort, 50.4%
(n= 399) of women were <55 years of age. The majority of the
sample was non-African American population (93.2%, n= 738).
More than 70% (n= 560) of women were ER/PR positive with
27.8% women with ER/PR negative status. HER 2 positive sta-
tus was reported in 261 women (33.0%) and 464 women (58.6%)
were reported as negative status. More than half of women had
metastasis on bone (67.7%) and visceral site (65.8%), while 26 and
30% of women were presented as brain and soft tissue metastasis,
respectively. See Table 1.
SURVIVAL RELATIONSHIPS WITH DEMOGRAPHIC AND TUMOR
CHARACTERISTICS
Median survival of the cohort was 32 months and mean survival
42.5 months (SE 1.4). The 5-year survival rate was 24%. Some
demographics and tumor characteristics were associated with
shorter survival from the diagnosis of MBC (Table 1). Increas-
ing numbers of metastatic sites, ER/PR negativity, HER 2 negative
status were associated with worse survival. Additionally, women
with brain and visceral metastasis compared with non-metastasis
of the relevant site had poor prognosis (Figures 1 and 2); these
relationships were constantly observed when stratified by HER 2
status. Among both women with HER 2 positive and negative sta-
tus, women without brain and visceral metastasis were likely to
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Table 1 | Survival difference according to demographic and tumor
characteristics.
Variable No. (%) Mean (SE)
montha
Median
montha
P -value*
Ageb
<55 years 399 (50.4) 44.7 (1.98) 33.0 0.0840
≥55 years 393 (49.6) 36.6 (1.43) 31.0
Race
Non-African American 738 (93.2) 42.6 (1.44) 32.0 0.6970
African American 54 (6.8) 38.0 (4.51) 31.0
Number of metastatic sites
1 192 (24.3) 52.2 (3.01) 46.0 <0.0001
2 229 (28.9) 42.7 (2.81) 29.0
3+ 371 (46.8) 37.5 (1.54) 32.0
Metastatic location
Bone 536 (67.7) 42.2 (1.57) 33.0 0.8731
Brain 205 (25.9) 36.2 (1.92) 29.0 0.0084
Visceral 521 (65.8) 38.2 (1.47) 30.0 <0.0001
Soft tissue 238 (30.1) 41.6 (2.42) 32.0 0.6067
Other 175 (22.1) 44.4 (2.73) 37.0 0.0851
ER/PR statusc
ER/PR positive 560 (70.7) 46.4 (1.69) 38.0 <0.0001
ER/PR negative 220 (27.8) 32.1 (2.13) 22.0
HER 2 statusc
HER 2 positive 261 (33.0) 44.6 (2.09) 38.0 0.0199
HER 2 negative 464 (58.6) 40.2 (1.80) 30.0
SE, Standard error; ER/PR, estrogen receptor and/or progesterone receptor; HER
2, human epidermal growth factor receptor-2.
aSurvival was defined as interval in month between metastatic breast cancer
diagnosis and death or study end point.
*Relationship between variable and survival was evaluated using Log-rank test.
bAge variable was classified using median age (=55 years).
cUnknown ER/PR (n=12) or Her 2 (n=67) were excluded from analysis.
have longer survival than women with metastasis of the relative
site. In addition, when categorized by ER/PR status, among women
with ER/PR positive status, those who did not have brain and vis-
ceral metastasis had longer survival than those who had brain and
visceral metastasis respectively.
SEQUENTIAL CHEMOTHERAPY REGIMEN
Sequential chemotherapy regimen, independent of other systemic
treatments, was analyzed for treatment duration and survival from
completion of that set of chemotherapies (Table 2). The number of
sequential chemotherapy regimens ranged from 1 chemotherapy
regimen treatment through 13 different sequential chemotherapy
regimens for MBC. After the first MBC chemotherapy regimen
and through subsequent regimens of chemotherapy, median dura-
tions of therapy were 2–3 months with ranges from 1 to 81 month
durations. Median survivals from discontinuation of sequential
chemotherapy regimens were no more than 6 months following
the second sequential chemotherapy regimen. Range of survival
however was large ranging from 0 to 129 months. Even following
sixth line chemotherapy regimen the range of survival extended
to 36 months. It thus appears that in MBC, there are decreasing
subsets of women who achieve months of clinical benefit and
of survival even after receiving multiple sequential regimens of
chemotherapy.
Individual tumor characteristics influence response to
chemotherapy. We found that ER/PR and HER status modified
the relationships between sequences of chemotherapy regimen
and median months of therapy duration and survival from com-
pletion of treatment. When data were collapsed into first regi-
men of chemotherapy, second, and three or greater regimens of
chemotherapy, ER/PR status was minimally predictive (Table 3)
and HER 2 status was strongly predictive of the median months of
chemotherapy regimen duration and median months of survival
from completion of chemotherapy regimen treatment (Table 4).
Across sequences of chemotherapy regimen, women with HER
2 positive had longer median duration of chemotherapy regi-
men and improved median survival from the last chemotherapy
regimen.
DISCUSSION
The results from this study and the current literature illuminate
the reasons for the pattern of sequential chemotherapy use among
patients with MBC. This heterogeneous response to breast cancer
chemotherapy, even in women who have been heavily pre-treated
makes generalized predictions about survival particularly difficult,
often resulting in overly optimistic physician communication and
patients’ poor understanding regarding the reality and impact of
their disease status (17). The heterogeneity in response and wide
ranges of potential duration of benefit and survival from termi-
nation of treatment in a small subset of women has prompted
clinicians to base decisions for all women on the survival outliers
rather than the median survival, prompting the recommendation
of continuation of sequential chemotherapy until close to death.
Looking at these data only in terms of the outliers is problem-
atic. The data indicate that the discontinuation of third metastatic
chemotherapy regimen is the point of illness in MBC when the
median survival is <6 months. This 6 month prognosis is the clas-
sic delineation for initiation of hospice and palliative care (17).
Among this cohort however, reliance on median survivals and
waiting for this 6 month survival time point for end of life coun-
seling will ignore the needs of almost half of the women who
will die prior to that point. Of the cohort who began chemother-
apy, only 31.6% (n= 201) began fourth line chemotherapy. The
end of life needs, such as hospice and palliative care referrals, of
the majority cannot be ignored by clinicians who have enthusi-
asm regarding potential survival benefit for a small minority of
women (18–21). Additionally, there are some demographic and
tumor characteristics that predict poor response to treatment and
overall survival. These variables, including hormone status, HER
2 status, and increased number and type of metastatic sites have
been established (22) and were confirmed by this sample. The
presence or absence of these variables allows for some tailoring
of counseling regarding “what to expect” rather than counseling
all women with the same message of “control not cure.” Counsel-
ing needs to incorporate the median durations of treatment, and
survival with some tailoring for individual characteristic’s, rather
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FIGURE 1 | Kaplan–Meier’s curve of survival by visceral metastasis status.
FIGURE 2 | Kaplan–Meier’s curve of survival by brain metastasis status.
than only emphasizing the few women with continued clinical
benefit to sequential therapy. Additionally because some women
with high risk disease do die quickly from MBC, some counseling
regarding the terminal nature of MBC needs to be incorporated at
the diagnosis of MBC.
A well-known 1985 essay, “The Median Isn’t the Message” was
written by a scientist diagnosed with a rare abdominal mesothe-
lioma and subsequent poor life prognosis (23). He analyzed the
probabilities of living longer than the median survival for his spe-
cific disease and wrote an essay extolling the virtues of a positive
attitude and “raging mightily against the dying of the light (23).”
While he enjoyed a 20-year remission of his disease and did fall into
the positive tail of the survival curve, it is important to remem-
ber that he was an outlier. To counsel all patients to expect to live
20 years when the median survival is much less is not honest and
places an undue burden on the patient to “be positive” without
strong scientific evidence that attitudes alone can influence the
course of disease (24, 25).
These honest conversations that need to occur at the diagno-
sis of MBC and throughout the course of illness are difficult and
require time and skill. The American Society of Clinical Oncol-
ogy (ASCO) released a statement in January 2011 emphasizing
the need for individualized care for all patients with cancer (26).
They conclude that conversations regarding “realistic conversa-
tions regarding prognosis, the potential benefits of and limitations
of disease directed therapy, and the potential role of palliative care,”
in conjunction with or as an alternative to disease directed ther-
apy occur late in the cancer therapy and should occur earlier and
consistently. While ASCO focuses on the conversations between
physician and patient, nurses can be instrumental in ensuring that
all women receiving care for MBC are following an individual-
ized plan of care, tailored to their specific risk and care needs.
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Nurse can assess a women’s understanding of her disease and treat-
ment plan and treatment goals, advocating for patient/physician
conversations to occur, encourage patients to discuss questions
or concerns with physicians, or in the case of advanced practice
nursing, become skilled in these conversations themselves (27).
Table 2 | Distribution of treatment durations of sequential
chemotherapy regimen and survival from completion of the
sequential treatment.
Sequence of
chemotherapy
regimen
No. (%) Median month
and range of
sequential
chemotherapy
regimen
Median month and
range of survival from
completion of
sequential
chemotherapy regimen
1 636 (100) 4.0 (1–64) 13.0 (0–129)
2 443 (69.7) 3.0 (1–33) 7.0 (0–117)
3 304 (47.8) 2.0 (1–24) 5.0 (0–114)
4 201 (31.6) 3.0 (1–81) 5.0 (0–42)
5 129 (20.3) 3.0 (1–17) 4.0 (0–41)
6 85 (13.4) 2.0 (1–16) 3.0 (0–36)
7 51 (8.0) 2.0 (1–11) 3.0 (0–29)
8 27 (4.2) 2.0 (1–12) 2.0 (0–17)
9 17 (2.7) 1.0 (1–5) 2.0 (0–15)
10 7 (1.1) 2.0 (1–6) 6.0 (1–10)
11 4 (0.6) 2.0 (1–6) 3.5 (1–8)
12 2 (0.3) 2.5 (2–3) 3.0 (1–5)
13 2 (0.3) 1.5 (1–2) 1.5 (0–3)
Ongoing analysis from several MBC cohorts (28, 29) over
the course of several decades has shown a progressive increase
in MBC survival, attributed in part to more aggressive sys-
temic therapies. Our analysis points out that a small num-
ber of women do have wide ranges of survival even with late
sequence chemotherapy regimen. The women who have clin-
ical benefit from late sequential therapies of chemotherapy
are intriguing and need to be analyzed in a more systematic
fashion. This systematic analysis should include demographic
and original tumor factors, previous treatment patterns, char-
acteristics of the metastatic disease and possible changes in
tumor characteristics throughout MBC therapy. Genomic analy-
sis through micro array and immunohistochemistry technologies
may potentially add new information to better understand a
favorable response in MBC allowing a more tailored approach
to MBC (30).
There are limitations to this analysis. First, the nature of retro-
spective study and chart abstraction in women who have multiple
care providers, even multiple cancer care providers, leaves a large
amount of sequential data incomplete, or completely missing. Sec-
ondly, the question of clinical benefit must include quality of life,
overall patient distress, and symptom scores, none well established
through retrospective chart review. Symptom and quality of life
assessment must be incorporated in real time clinical practice,
using clinically relevant quality of life scales.
CONCLUSION
There is not a strong evidence base for sequences of chemother-
apy regimen treatment for MBC, making treatment decision and
Table 3 | Median months of sequential chemotherapy regimen and survival from completion of sequential treatment, stratified by ER/PR status.
Sequence of
chemotherapy regimen
No. Median month (No.) of sequential
chemotherapy regimen
Median month (No.) of survival from completion
of sequential chemotherapy regimen
ER/PR positive ER/PR negative P -value* ER/PR positive ER/PR negative P -value*
1 626 5.0 (420) 4.0 (206) 0.0283 14.0 (420) 11.0 (206) 0.0891
2 436 4.0 (280) 3.0 (156) 0.0006 9.0 (280) 6.0 (156) 0.0925
3+ 302 6.0 (196) 5.5 (106) 0.4300 7.0 (196) 8.5 (106) 0.9207
ER/PR, estrogen receptor and/or progesterone receptor.
*Significant difference of median months of sequential chemotherapy regimen or survival from the sequential treatment between ER/PR positive and negative was
evaluated using Wilcoxon rank sum test.
Table 4 | Median months of sequential chemotherapy regimen and survival from completion of sequential treatment, stratified by HER 2 status.
Sequence of
chemotherapy regimen
No. Median month (No.) of sequential
chemotherapy regimen
Median month (No.) of survival from completion
of sequential chemotherapy regimen
HER 2 positive HER 2 negative P -value* HER 2 positive HER 2 negative P -value*
1 598 5.0 (240) 4.0 (358) 0.0018 19.0 (240) 10.5 (358) <0.0001
2 419 4.0 (173) 3.0 (246) 0.0584 10.0 (173) 6.0 (246) 0.0001
3+ 289 9.0 (132) 4.0 (157) <0.0001 16.0 (132) 4.0 (157) <0.0001
HER 2, human epidermal growth factor receptor-2.
*Significant difference of median months of sequential chemotherapy regimen or survival from the sequential treatment between HER 2 positive and negative was
evaluated using Wilcoxon rank sum test.
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end of life counseling in MBC a challenge for cancer care pro-
fessionals. It is appropriate to be hopeful about each new ther-
apy, but with counseling that encompasses a “hope for the best
but prepare for the worst” (31) content, rather than a “MBC
is a chronic illness with unlimited treatment option approach.”
Clinicians must also consider that despite some promise of
late stage clinical benefit, intensive sequential treatment span-
ning many months and even years is not without larger emo-
tional and financial consequence for patients and surviving family
(31, 32).
The ASCO statement suggests that instead of each new line
of chemotherapy becoming the immediate “default” after can-
cer progression, a new discussion of treatment goals, patient’s
understanding of risk and benefit, and a clear explanation of costs
including monetary, time, and toxicity be offered. Each sequential
chemotherapy regimen then becomes a new decision. ASCO also
emphasizes that patients wanting a therapy does not preclude the
necessity of having a conversation regarding the likelihood of true
benefit from that treatment. These conversations are extremely
difficult in MBC due to the occasional outlier in response to a
late line of chemotherapy. All patients believe they will be “the
one” to respond, rather than believing that it is likely that they
will be within the median. Although difficult, it is the clinician’s
responsibility to offer hopeful but realistic counseling (33, 34).
These results have implication for (1) greater attention to qual-
ity of life endpoints, (2) creation of randomized controlled trials
evaluating efficacy of sequential MBC therapies, (3) guidance
for initiation of Phase I trials in the MBC treatment course, (4)
reassessment of hospice criteria to allow both hospice care and pal-
liative chemotherapy due to the heterogeneity in chemotherapy
response and quality of life benefit with palliative chemother-
apy, (5) methods to determine financial implication (patient and
payer) of sequential MBC palliative care, and (6) incentive to bet-
ter understand the unique characteristics of the long term MBC
survivors for better prognostic and predictive information. This
additional information will better inform the clinician charged
with patient counseling as metastatic patient counseling treatment
commences.
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